Disease Landscape and Forecast Insights

Agents for treating major depressive disorder (MDD) span multiple drug classes; while selective serotonin reuptake inhibitors (SSRIs) and serotonin / norepinephrine reuptake inhibitors (SNRIs) are…

Clarivate Epidemiology’s coverage of obsessive-compulsive disorder (OCD) comprises epidemiological estimates of key patient populations in the European countries (Austria, Belgium, Czech Republic…

Clarivate Epidemiology’s coverage of obsessive-compulsive disorder (OCD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

Most psychiatrists define TRS as a lack of response to at least two treatment changes. Currently, clozapine is the only approved drug for this condition, but its use is limited due to safety…

Clarivate Epidemiology’s coverage of post-traumatic stress disorder comprises epidemiological estimates of key patient populations across seven countries worldwide. We report the prevalence of post…

Clarivate Epidemiology’s coverage of binge eating disorder (BED) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Clarivate Epidemiology’s coverage of binge eating disorder (BED) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Managing the frequency and severity of psychotic episodes is the primary goal in the treatment of schizophrenia. Atypical antipsychotics are the preferred drug class, driven by physicians’…

Major depressive disorder (MDD) is typically treated with psychotherapy, pharmacotherapy, or a combination of the two. The MDD therapy market is highly genericized; for patients experiencing…

Clarivate Epidemiology’s coverage of social anxiety disorder comprises epidemiological estimates of key patient populations across seven countries worldwide. We report the prevalence of social…

The number of total prevalent cases of SAD in the countries under study will increase by 7% from 21 million to 23 million in 20 years. Of the countries considered in this analysis, the total…

Clarivate Epidemiology’s coverage of insomnia comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of…